Small Stocks, Big Money™

VSee Health (Nasdaq: VSEE) received a $2 million, two-year contract renewal with a top 50 hospital system, doubling the hospitals coverage of neurocritical care beds and integrating autonomous robotics into patient monitoring. This expansion reinforces VSee Health’s position as a leader in AI-powered telehealth, leveraging its digital health ecosystem to drive efficiency and enhance patient outcomes. With the introduction of its groundbreaking telenursing model, the company is poised to disrupt the industry by addressing workforce shortages through AI-driven automation and remote care solutions.

Trinity Biotech (Nasdaq: TRIB) reported significant first-day accuracy improvements in its next-generation continuous glucose monitoring (CGM) system, with a 35% boost in Mean Absolute Relative Difference (MARD) and over 50% improvement in Mean Absolute Difference (MAD) compared to previous models. These advancements address a longstanding industry challenge—accuracy fluctuations in the first 24 hours of CGM use—enhancing reliability and user confidence. With superior signal quality, enhanced post-insertion stability, and industry-standard low-glucose precision, Trinity’s CGM is positioned to set new benchmarks in affordability, sustainability, and performance ahead of its planned European regulatory submission in 2025.

OS Therapies (NYSE American: OSTX) is making significant strides in its mission to bring OST-HER2 to market for osteosarcoma, following strong Phase 2b trial results and a well-funded regulatory pathway. With $13.1 million raised over the past six months, the company is fully capitalized through key FDA milestones, including its planned Biologics Licensing Application (BLA) submission in late 2025. Additionally, OS Therapies’ pending acquisition of Ayala’s Listeria-based immunotherapy assets strengthens its pipeline while significantly improving future commercial margins. Looking ahead, the company is exploring strategic options for its tunable Antibody Drug Conjugate platform, reinforcing its position as a leader in immunotherapy innovation.

Jupiter Neurosciences (Nasdaq: JUNS) has secured a manufacturing agreement with Catalent to produce JOTROL™ softgel capsules for its upcoming Phase 2a clinical trial in Parkinson’s disease. JOTROL, a next-generation resveratrol-based therapeutic, is designed to enhance bioavailability while minimizing gastrointestinal side effects—addressing a key limitation of previous formulations. With the global Parkinson’s market projected to exceed $14 billion by 2030, this partnership marks a critical step in advancing JOTROL toward commercialization, as Jupiter continues to explore additional indications in neurodegenerative diseases.